π‘ RADAR REPORT
Wednesday, 18 November 2026 Β· data as of 2026-11-18 14:04 UTC
ACTIVE TRIALS8,747
P3 READOUTS Β· 14D40
P3 READOUTS Β· 30D130
CHANGES Β· 7D157
LATE >6 MONTHS46%
Phase 3 readouts due Β· next 14 days
40 trials with an exact primary-completion date in the next two weeks (130 in the next 30 days).
| Date | Trial | Sponsor | Area | N | vs. original plan |
|---|---|---|---|---|---|
| 2026-11-18 est. | POETYK SjS-1 | Bristol-Myers Squibb $BMY | Immuno | 774 | +0.0 mo |
| 2026-11-18 est. | Drugs-SNPs | Medicine Invention Design, Inc | Oncology | 600 | +30.0 mo |
| 2026-11-20 est. | Pembrolizumab | Merck Sharp & Dohme LLC $MRK | Oncology | 990 | +17.1 mo |
| 2026-11-21 est. | Cabergoline tablets | Changchun GeneScience Pharmaceutical Co., Ltd. | Cardio-Met | 382 | +14.0 mo |
| 2026-11-23 est. | Investigational varicella vaccine | GlaxoSmithKline $GSK | Infectious | 750 | +4.4 mo |
| 2026-11-23 est. | dTpa | GlaxoSmithKline $GSK | Infectious | 102 | β |
| 2026-11-24 est. | KarXT | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Neuro | 406 | +0.8 mo |
| 2026-11-24 est. | Avelumab | EMD Serono Research & Development Institute, Inc. $MRK.DE | Oncology | 205 | +33.9 mo |
| 2026-11-24 est. | 177Lu-DOTATATE injection | HTA Co., Ltd. | Other | 184 | +0.0 mo |
| 2026-11-25 est. | ICP-332 Tablets | Beijing InnoCare Pharma Tech Co., Ltd. | Immuno | 552 | +0.0 mo |
| 2026-11-25 est. | rilzabrutinib | Sanofi $SNY | Cardio-Met | 3 | -0.2 mo |
| 2026-11-26 est. | RUBY | Tesaro, Inc. | Oncology | 785 | +60.0 mo |
| 2026-11-26 est. | MT1013 | Shaanxi Micot Pharmaceutical Technology Co., Ltd. | Cardio-Met | 424 | +0.0 mo |
| 2026-11-28 est. | Yellow fever vaccine (live) | Sanofi $SNY | Infectious | 2440 | +3.7 mo |
| 2026-11-29 est. | Rimegepant | Pfizer $PFE | Neuro | 723 | +5.9 mo |
| 2026-11-30 est. | D-0502 | InventisBio Co., Ltd | Oncology | 640 | +0.0 mo |
| 2026-11-30 est. | Atezolizumab | Hoffmann-La Roche $RO.SW | Oncology | 382 | -8.1 mo |
| 2026-11-30 est. | Drug:WD-890 | Zhejiang Wenda Pharma Technology LTD. | Immuno | 375 | β |
| 2026-11-30 est. | A166 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. $6990.HK | Oncology | 365 | +12.0 mo |
| 2026-11-30 est. | SL1002 | Saol Therapeutics Inc | Neuro | 150 | +0.0 mo |
| 2026-11-30 est. | Neuroncell-EX | Cytopeutics Sdn. Bhd. | Cardio-Met | 80 | +21.7 mo |
| 2026-11-30 est. | GS1191-0445 injection | Gritgen Therapeutics Co., Ltd. | Rare | 50 | +0.0 mo |
| 2026-11-30 est. | TS-172 20~60 mg/day | Taisho Pharmaceutical Co., Ltd. | Other | 34 | β |
| 2026-11-30 est. | Leniolisib | Pharming Technologies B.V. | Other | 15 | +29.7 mo |
| 2026-11-30 est. | AVTX-803 (L-Fucose) | AUG Therapeutics | Other | 4 | +47.0 mo |
Registry changes Β· last 7 days
Phase 3 / 2-3 trials whose ClinicalTrials.gov record changed (status, readout date, enrollment, sites), plus stops and results posted.
| Trial | Sponsor | Change |
|---|---|---|
| WONDERS1 | Gilead Sciences $GILD | Active, not recruiting β Terminated |
| SSGJ-707 | Shenyang Sunshine Pharmaceutical Co., LTD. | Recruiting β Terminated |
| X-NOVA2 | Xenon Pharmaceuticals Inc. $XENE | Active, not recruiting β Terminated |
| Nogapendekin alfa inbakicept (NAI) | ImmunityBio, Inc. | Not yet recruiting β Withdrawn |
| NMS-03305293 | Nerviano Medical Sciences | Active, not recruiting β Terminated |
| AB-3028 | Arsenal Biosciences, Inc. | Active, not recruiting β Terminated |
| BNT162b2 | BioNTech SE $BNTX | readout 2027-04-21 β 2027-04-12 (-0.3 mo) |
| WONDERS1 | Gilead Sciences $GILD | readout 2028-01 β 2026-11-03 (-13.9 mo) |
| CEVOLUTION | Hoffmann-La Roche $RO.SW | readout 2028-10-31 β 2028-11-30 (+1.0 mo) |
| AND017 | Kind Pharmaceuticals LLC | readout 2026-12-01 β 2027-03-01 (+3.0 mo) |
| AND017 capsules | Kind Pharmaceuticals LLC | readout 2026-10-30 β 2027-02-20 (+3.7 mo) |
| Tilrekimig | Pfizer $PFE | readout 2034-05-12 β 2034-04-21 (-0.7 mo) |
| CHAPTER-4 | Pharvaris Netherlands B.V. | readout 2028-12 β 2031-08-19 (+32.6 mo) |
| SSGJ-707 | Shenyang Sunshine Pharmaceutical Co., LTD. | readout 2026-07-30 β 2026-02-01 (-5.9 mo) |
| OLYMPUS | Vertex Pharmaceuticals Incorporated $VRTX | readout 2028-12-29 β 2029-06-27 (+5.9 mo) |
| X-NOVA2 | Xenon Pharmaceuticals Inc. $XENE | readout 2026-10 β 2026-10-28 (+0.9 mo) |
| Debio 4326 | Debiopharm International SA | readout 2026-10 β 2026-10-09 (+0.3 mo) |
| VIGILANT | GlaxoSmithKline $GSK | readout 2029-04-30 β 2029-04-02 (-0.9 mo) |
| MAESTRA 2 | Incyte Corporation $INCY | readout 2028-11-15 β 2027-10-12 (-13.1 mo) |
| ACS | Novartis Pharmaceuticals $NVS | readout 2027-02-11 β 2027-01-16 (-0.9 mo) |
| SPN-812 | Supernus Pharmaceuticals, Inc. | readout 2026-09 β 2026-12 (+3.0 mo) |
| ICM ADX-2191 injection | Aldeyra Therapeutics, Inc. | readout 2026-12 β 2029-12 (+36.0 mo) |
| DuraSTAR | GlaxoSmithKline $GSK | readout 2029-12-12 β 2030-03-13 (+3.0 mo) |
| WILL-EMI | Hoffmann-La Roche $RO.SW | readout 2027-04-30 β 2027-10-06 (+5.2 mo) |
| Citicoline eye drops 2% | Omikron Italia S.r.l. | readout 2026-04-01 β 2029-07-01 (+39.0 mo) |
| RASolute 303 | Revolution Medicines, Inc. $RVMD | readout 2028-06 β 2028-04 (-2.0 mo) |
| Sinovac rabies vaccine | Sinovac Biotech Co., Ltd | readout 2026-09-30 β 2026-07-15 (-2.5 mo) |
| Zasocitinib | Takeda $TAK | readout 2033-01-24 β 2034-07-03 (+17.2 mo) |
| IPAX BrIGHT | Telix Pharmaceuticals (Innovations) Pty Limited | readout 2027-07 β 2028-07 (+12.0 mo) |
| OPTIMA | Regeneron Pharmaceuticals $REGN | results posted |
Delay Index
Across 5,371 active trials registered more than a year ago, 46% have moved their readout date by more than 6 months since first registration.
Most often late
| Sponsor | Trials | >6 mo late |
|---|---|---|
| Acerta Pharma BV | 11 | 91% |
| Ionis Pharmaceuticals, Inc. $IONS | 12 | 83% |
| Taiho Oncology, Inc. | 10 | 70% |
| Allist Pharmaceuticals, Inc. | 12 | 67% |
| Seagen, a wholly owned subsidiary of Pfizer $PFE | 12 | 67% |
Most on time
| Sponsor | Trials | On time Β±1 mo |
|---|---|---|
| Qilu Pharmaceutical Co., Ltd. | 33 | 88% |
| Ono Pharmaceutical Co., Ltd. $4528.T | 13 | 85% |
| Shanghai JMT-Bio Inc. | 12 | 83% |
| Biocad | 12 | 83% |
| Dizal Pharmaceuticals | 11 | 82% |
FDA this week
New NDA/BLA approvals and Class I drug recalls (last 7 days), and manufacturing (CGMP) or trial-conduct warning letters (last 14 days).
| Type | What | Company | Date |
|---|---|---|---|
| β Approval | KLYGEFA (gefurulimab) | ALEXION PHARM $AZN | 2026-11-13 |
| β Approval | PEBRILZO (pertuzumab) | BIOCON BIOLOGICS INC | 2026-11-12 |
New Phase 3 trials Β· last 7 days
29 Phase 3 / 2-3 trials were first posted on ClinicalTrials.gov.
| Trial | Sponsor | Area | N |
|---|---|---|---|
| PINNACLE-MI | Novartis Pharmaceuticals $NVS | Cardio-Met | 10000 |
| Frexalimab | Sanofi $SNY | Neuro | 2500 |
| Fenebrutinib | Hoffmann-La Roche $RO.SW | Neuro | 1800 |
| Prevention of pneumococcal disease from 24 seroty⦠| Reinovax Biologics Co., LTD | Infectious | 1260 |
| AMBITION 3 | Novo Nordisk A/S $NVO | Cardio-Met | 1200 |
| AMBITION4 | Novo Nordisk A/S $NVO | Cardio-Met | 1060 |
| PROST-3 | Tasly Biopharmaceuticals Co., Ltd. | Other | 978 |
| Berobenatide | Pfizer $PFE | Cardio-Met | 900 |
| DTaP-IPV-HB-PRP~T combined vaccine | Sanofi $SNY | Infectious | 720 |
| Ris-Rez | GlaxoSmithKline $GSK | Oncology | 700 |
| RC118(Dose 1) plus RC148(Dose 1) | RemeGen Co., Ltd. | Oncology | 680 |
| Ragweed Pollen Skin Prick Test Solution (3,500 DU⦠| Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. | Immuno | 650 |
| NOBLEHEART-HCM | Braveheart Bio, Inc. $BRVE | Cardio-Met | 600 |
| ABBV-722 | AbbVie $ABBV | Immuno | 580 |
| LP-003 Injection | Longbio Pharma | Immuno | 514 |
Post text
Ready to paste on LinkedIn or X.
π‘ DataCutoff Radar Report Β· 18 Nov 2026 β± 40 Phase 3 readouts due in the next 14 days (130 in 30): β’ 2026-11-18 β POETYK SjS-1 (Bristol-Myers Squibb $BMY, Immuno) β’ 2026-11-18 β Drugs-SNPs (Medicine Invention Design, Inc, Oncology) β’ 2026-11-20 β Pembrolizumab (Merck Sharp & Dohme LLC $MRK, Oncology) β’ 2026-11-21 β Cabergoline tablets (Changchun GeneScience Pharmaceutical Co., Ltd., Cardio-Met) β’ 2026-11-23 β Investigational varicella vaccine (GlaxoSmithKline $GSK, Infectious) π Registry changes this week: β’ WONDERS1 (Gilead Sciences $GILD): Active, not recruiting β Terminated β’ SSGJ-707 (Shenyang Sunshine Pharmaceutical Co., LTD.): Recruiting β Terminated β’ X-NOVA2 (Xenon Pharmaceuticals Inc. $XENE): Active, not recruiting β Terminated β’ Nogapendekin alfa inbakicept (NAI) (ImmunityBio, Inc.): Not yet recruiting β Withdrawn π Delay Index: 46% of active trials (registered >1 yr ago) have pushed their readout >6 months. Most often late: Acerta Pharma BV 91%, Ionis Pharmaceuticals, Inc. 83%, Taiho Oncology, Inc. 70% β FDA: KLYGEFA approved (ALEXION PHARM); PEBRILZO approved (BIOCON BIOLOGICS INC) Full report & live map: https://datacutoff.com/report/ Data: ClinicalTrials.gov, openFDA, fda.gov. Not investment advice.
Sources: ClinicalTrials.gov (U.S. NLM), openFDA and fda.gov warning letters. Primary completion dates are sponsor-reported and often estimates; readout = last primary-endpoint data collected, not results publication. For information only β not investment or medical advice. Disclaimer